UK Edition. Click here for US version.
IRINOTECAN EGIS 20MG/ML CONCENTRATE FOR SOLUTION FOR INFUSIONView full screen / Print PDF » Download PDF ⇩
Irinotecan hydrochloride trihydrate
The name of the product is Irinotecan EGIS 20 mg/ml concentrate for solution
for infusion and will be referred to as Irinotecan EGIS solution throughout this
Read all of this leaflet carefully before you start using this medicine.
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor.
This medicine has been prescribed for you. Do not pass it on to others. It may
them, even if their symptoms are the same as yours.
If any of the side effects gets serious, or if you notice any side effects not
listed in this leaflet, please tell your doctor.
In this leaflet:
What Irinotecan EGIS solution is and what it is used for
Before you are given Irinotecan EGIS solution
How Irinotecan EGIS solution will be given to you
Possible side effects
How to store Irinotecan EGIS solution
WHAT IRINOTECAN EGIS SOLUTION IS AND WHAT IT IS USED
Irinotecan EGIS solution belongs to a group of medicines called cytostatics (anticancer medicines).
It is used for the treatment of advanced cancer of the colon and rectum in adults,
either alone or in combination with other medicines.
Your doctor may use Irinotecan EGIS together with:
• 5-fluorouracil/folinic acid (5-FU/FA) and bevacizumab to treat cancer of the
colon or rectum.
• cetuximab to treat cancer of the large intestine that has epidermal growth
• capecitabine with or without bevacizumab to treat cancer of the colon or
BEFORE YOU ARE GIVEN IRINOTECAN EGIS SOLUTION
You should not be given Irinotecan EGIS solution if any of the following apply to
Tell your doctor or hospital pharmacist if
you are allergic (hypersensitive) to irinotecan hydrochloride trihydrate or to any
of the ingredients of Irinotecan EGIS solution (see list of ingredients in section
6 Further Information)
you have any other bowel disease or a history of bowel obstruction
you are pregnant or breast-feeding or if you think you might be pregnant
you have any liver problems
you have a problem with your bone marrow
you have been told by your doctor that you have an intolerance to some sugars,
as this medicine contains sorbitol (E420)
you are taking St John’s Wort, a herbal remedy used for depression and sleep
you are in a poor general health
Tell your doctor before you are treated with Irinotecan EGIS if you have any kidney
If your doctor tells you that you will also be receiving cetuximab or bevacizumab or
capecitabine with your Irinotecan EGIS please make sure you also read the patient
information leaflet for cetuximab or bevacizumab or capecitabine.
Take special care with Irinotecan EGIS solution
This medicine is intended for adults only. Check with your doctor if this medicine has
been prescribed for use in a child.
Special care is also needed for elderly patients.
As Irinotecan EGIS solution is an anti-cancer medicine it will be administered to you
in a special unit and under the supervision of a doctor qualified in the use of anticancer medicines. The unit’s personnel will explain to you what you need to take
special care of during and after the treatment. This leaflet may help you to remember
1. The first 24 hours after administration of Irinotecan EGIS solution
During administration of Irinotecan EGIS solution (30 – 90 min) and within 24 hours
after administration you may experience some of the following symptoms: diarrhoea,
abdominal pain, red, sore, itching or weeping eyes (conjunctivitis), running nose
(rhinitis), low blood pressure, widening of the blood vessels, sweating, chills, a
feeling of general discomfort and illness, dizziness, visual disturbance, pupil
contraction, watering eyes and excessive mouth-watering. The medical term for these
symptoms is acute cholinergic syndrome which can be treated (with atropine). If you
have any of these symptoms immediately tell your doctor who will give you any
1. From the day after treatment with Irinotecan EGIS solution until the next
During this period you may experience various symptoms, which may be serious and
require immediate treatment and close supervision.
If your diarrhoea starts more than 24 hours after administration of Irinotecan EGIS
solution (“delayed diarrhoea”) it may be serious. It is often seen about 5 days after
administration. The diarrhoea should be treated immediately and kept under close
supervision. Immediately after the first liquid stools do the following:
1. Immediately inform your doctor who is supervising the treatment and tell
him/her about the diarrhoea. If you are not able to reach the doctor, contact the
unit at the hospital supervising the Irinotecan EGIS solution treatment. It is
very important that they are aware of the diarrhoea.
2. Take any anti-diarrhoeal treatment that the doctor has given you exactly as
he/she has told you. The treatment may not be changed without consulting the
doctor. Recommended anti-diarrhoeal treatment is loperamide (4 mg for the
first intake and then 2 mg every 2 hours, also during the night). This should be
continued for at least 12 hours after the last liquid stools. The recommended
dosage of loperamide may not be taken for more than 48 hours.
3. Drink large amounts of water and rehydration fluids immediately (such as water,
water, fizzy drinks, soup or oral rehydration therapy).
You must immediately tell the doctor, or the unit supervising the treatment, if:
you have nausea, vomiting or any fever as well as diarrhoea
you still have diarrhoea 48 hours after starting the diarrhoea treatment.
Note: Do not take any treatment for diarrhoea other than that given to you by your
doctor and the fluids described above. Follow the doctor’s instructions. The antidiarrhoeal treatment should not be used to prevent a further episode of diarrhoea, even
if you have experienced delayed diarrhoea at previous cycles.
If the body temperature increases over 38ºC it may be a sign of infection, especially if
you also have diarrhoea. If you have any fever (over 38ºC) contact your doctor or the
unit immediately so that they can give you any treatment necessary.
Nausea and vomiting
If you have nausea and/or vomiting contact your doctor or the unit immediately.
Irinotecan EGIS solution may cause a decrease in the number of some of your white
blood cells, which play an important role in fighting infections. This is called
neutropenia. Neutropenia is often seen during treatment with irinotecan and is
reversible. Your doctor should arrange for you to have regular blood tests to monitor
these white blood cells. Neutropenia is serious and should be treated immediately and
If you have any fever this may be an indication of infection associated with this
neutropenia and requires immediate treatment.
If you have any breathing difficulties contact your doctor immediately.
Impaired Liver Function
Before treatment with Irinotecan EGIS solution is started and before every following
treatment cycle the liver function should be monitored (by blood tests).
If you have one or more of the symptoms mentioned, after you have returned home
from the hospital, you should immediately contact the doctor or the unit supervising
the Irinotecan EGIS solution treatment.
Impaired Kidney Function
As this medicine has not been tested in patients with kidney problems, please check
with your doctor if you have any kidney problems.
Taking other medicines
Please tell your doctor or pharmacist if you are taking or have recently taken any
other medicines, including medicines obtained without a prescription. This is also
valid for herbal medicines, strong vitamins and minerals.
Some medicines may alter the effects of Irinotecan EGIS solution, for example,
ketoconazole (for the treatment of fungal infections), rifampicin (for the treatment of
tuberculosis) and some medicines for the treatment of epilepsy (carbamazepine,
phenobarbital and phenytoin).
The herbal medicine St John’s Wort (Hypericumperforatum) may not be used at the
same time as Irinotecan EGIS solution and not between treatments, as it may decrease
the effect of irinotecan.
If you require an operation, please tell your doctor or anaesthetist that you are using
this medicine, as it may alter the effects of some medicines used during surgery.
Pregnancy and Breast-feeding
Irinotecan EGIS solution must not be used during pregnancy. Women of child-bearing
age should avoid becoming pregnant. Contraceptive measures must be taken by both
male and female patients during and for at least three months after cessation of
therapy. If you become pregnant during this period you must immediately inform
Breast-feeding must be discontinued for the duration of Irinotecan EGIS solution
Driving and using machines
In some cases Irinotecan EGIS solution may cause side effects which affect the ability
to drive and use tools and machines. Contact your doctor or pharmacist if you are
During the first 24 hours after administration of Irinotecan EGIS solution you may
feel dizzy or have visual disturbances. If this happens to you do not drive or use any
tools or machines.
Important information about the ingredients of Irinotecan EGIS solution
Irinotecan EGIS solution contains sorbitol. If you suffer from an intolerance to some
sugars, tell your doctor before you are given Irinotecan EGIS solution.
This medicinal product contains less than 1 mmol sodium per dose, therefore it can be
considered to be essentially “sodium-free”.
HOW IRINOTECAN EGIS SOLUTION WILL BE GIVEN TO YOU
Irinotecan EGIS solution will be given as an infusion into your vein over a period of
30 to 90 minutes.
The amount of Irinotecan EGIS solution you will be given depends on your age,
height, weight and general medical condition. It will also depend on any other
treatment you may have received for your cancer. Your doctor will decide what is the
right amount to use (the dose).
If you have previously been treated with 5-fluorouracil, you will normally be
treated with Irinotecan EGIS solution alone starting with a dose of 350 mg/m2
every 3 weeks.
If you have not had previous chemotherapy, you will normally receive
180 mg/m2 Irinotecan EGIS solution every 2 weeks. This will be followed by
folinic acid and 5-fluorouracil.
If you are to receive Irinotecan EGIS in combination with cetuximab, irinotecan
must not be given earlier than 1 hour after the end of the cetuximab infusion.
These dosages may be adjusted by your doctor depending on your condition and any
side effects you may have.
If you receive more Irinotecan EGIS solution than you should
Tell your doctor or care provider if you think that you have been given too much
Irinotecan EGIS solution. Acute overdosing worsens side effects like diarrhoea or
neutropenia (a decrease in the number of white blood cells in the blood). Should this
happen you will receive treatment to prevent dehydration. Your blood cell count will
be monitored and any infections treated accordingly.
POSSIBLE SIDE EFFECTS
Like all medicines Irinotecan EGIS solution can cause side effects, although not
everybody gets them.
Your doctor will discuss these side effects with you and explain the risks and benefits
of your medicine.
Very common side effects (more than 1 in 10 patients):
Blood disorders: Neutropenia (decreased number of some white blood cells) ,
thrombocytopenia (decreased number of blood platelets which makes you bruise
and bleed easily), anaemia
Nausea, and vomiting
Hair loss (the hair grows again at the end of treatment).
In combination therapy transient serum levels of some enzymes (ALT, AST,
alkaline phosphatase) or bilirubin
Common side effects (less than 1 in 10 patients):
Acute cholinergic syndrome: the main symptoms are defined as: early
diarrhoea, and various other symptoms such as abdominal pain, red, sore,
itching or weeping eyes (conjunctivitis), running nose (rhinitis), low blood
pressure, widening of blood vessels, sweating, chills, a feeling of general
discomfort and illness, dizziness, visual disturbances, pupil contraction,
watering eyes and increased salivation occurring during or within the first 24
hours after the infusion of Irinotecan EGIS solution.
Fever associated with a severe decrease in the number of some white blood
Loss of water (dehydration), commonly associated with diarrhoea and/or
Increase in levels of liver enzymes and creatinine in the blood
Uncommon side effects (less than 1 in 100 patients):
Mild skin reactions, mild reactions at the infusion site
Early effects such as breathing difficulties
Lung disease (interstitial pulmonary disease)
Abdominal pain and inflammation causing diarrhoea (a condition known as
Infrequent cases of renal insufficiency, low blood pressure or cardio-circulatory
failure have been observed in patients who experienced episodes of dehydration
associated with diarrhoea and/or vomiting or sepsis.
Rare side effects (less than 1 in 1,000 patients):
Severe allergic reactions (anaphylactic/anaphylactoid reactions. If this happens
you should tell your doctor immediately
Early effects such as muscular contraction or cramps and numbness
Gastrointestinal bleeding and inflammation of the colon including the appendix
Intestinal perforation, anorexia, abdominal pain, inflammation of the mucous
Inflammation of the pancreas
Increased blood pressure during and following administration
Decreased levels of potassium and sodium in the blood, mostly related to
diarrhoea and vomiting.
Very rare side effects (less than 1 in 10,000 patients):
Transient speech disorders
Increase in levels of some digestive enzymes which break down sugars and fats
If you receive Irinotecan EGIS in combination with cetuximab or bevacizumab, some
of the side effects you may experience can also be related to these combinations.
These may include acne-like rash. Therefore, please make sure you also read the
patient information leaflet for cetuximab or bevacizumab.
If you receive Irinotecan EGIS in combination with capecitabine, some of the side
effects you may experience can also be related to this combination. Such side effects
may include: very common blood clots, common allergic reactions, heart attack and
fever in patients with a low white blood cell count. Therefore, please make sure that
you also read the package leaflet for capecitabine.
If you receive Irinotecan EGIS in combination with capecitabine and bevacizumab,
some of the side effects you may experience can also be related to this combination.
Such side effects include: low white blood cell count, blood clots, high blood pressure
and heart attack. Therefore, please make sure that you also read the package leaflet for
If any of the side effects get serious, or if you notice any side effects not listed in
this leaflet, please tell your doctor or pharmacist.
HOW TO STORE IRINOTECAN EGIS SOLUTION
Keep out of the reach and sight of children.
Do not use Irinotecan EGIS solution after the expiry date which is stated on the vial
label and outer carton.
Keep the vial in the outer carton in order to protect from light.
For single use only.
Do not freeze.
After reconstitution and dilution under strict aseptic conditions, Irinotecan EGIS
solution must be used (infusion completed) immediately or within 24 hours if stored
in a refrigerator (2°C- 8°C).
If any cloudiness (precipitate) is observed in the vials or after reconstitution, the
product should be disposed of.
Your doctor must use the Irinotecan EGIS solution as soon as it has been made.
Vials that have already been used must be disposed of by your healthcare professional
according to hospital standard procedures applicable to cytotoxic medicines.
What Irinotecan EGIS solution contains
The active substance is irinotecan hydrochloride trihydrate 20 mg/ml.
The other ingredients are sorbitol E420, lactic acid, sodium hydroxide (for pH
adjustment), hydrochloric acid, concentrate (for pH adjustment) and water for
What Irinotecan EGIS solution looks like and contents of the pack
Irinotecan EGIS 20 mg/ml concentrate for solution for infusionis a clear, yellow
solution with pH at 3.0 - 4.0 and osmolarity at 265-320 mOsmol/kg. It must be diluted
before infusion into the patient.
It comes in two sizes:
1 x 40 mg of irinotecan hydrochloride trihydrate in a 2 ml type I amber glass,
rubber (bromobutyl, teflon-coated) stoppered vial
1 x 100 mg of irinotecan hydrochloride trihydrate in a 6 ml type I amber glass,
rubber (chlorobutyl, teflon-coated) stoppered vial.
Marketing Authorisation Holder and Manufacturer
The Marketing Authorisation Holder is:
EGIS Pharmaceuticals PLC
H-1106 Budapest, Keresztúri út 30-38.
The Manufacturers are:
Schiffgraben, D-38690, Vieneburg, Germany
EGIS Pharmaceuticals PLC
H-1106 Budapest, Keresztúri út 30-38.
This medicinal product is authorised in the Member States of the EEA under the
Irinotecan EGIS 20mg/ml concentrate for solution for infusion
Irinocol 20mg/ml Концентрат за инжекционен разтвор
Famagil 20mg/ml koncentrátum oldatos infúzióhoz
Ludiradol 20mg/ml concentrat pentru soluţie perfuzabilă
This leaflet was last approved in 04/2011.
------------------------------------------------------------------------------------------------------INFORMATION FOR HEALTHCARE PROFESSIONALS
Irinotecan EGIS 20 mg/ml concentrate for solution for infusion
Irinotecan hydrochloride trihydrate
The following information is intended for medical or healthcare professionals only:
Instructions for use – cytotoxic
Handling of Irinotecan EGIS
As with all other antineoplastic agents, caution should be exercised when handling
Irinotecan EGIS. Dilution should be carried out under aseptic conditions by trained
personnel in a designated area. Precautions should be taken to avoid contact with the
skin and mucous membranes.
Protection instructions for preparation of Irinotecan EGIS solution for infusion
1. Protective chamber should be used and protective gloves as well as protective
should be worn. If there is no protective chamber available mouth cover and
goggles should be used.
In the event of Irinotecan EGIS contact with the skin, the area should be rinsed
with plenty of running water and then washed with soap and water. In case of
contact with mucous membranes, wash the contacted area thoroughly with
water. If you have any discomfort, contact a doctor.
In case of contact of Irinotecan EGIS with eyes, wash them thoroughly with
plenty of water. Contact an ophthalmologist immediately.
Opened containers, like injection vials and infusion bottles and used cannulae,
syringes, catheters, tubes, and residuals of cytostatics should be considered as
hazardous waste and undergo disposal according to local guidelines for the
handling of HAZARDOUS WASTE.
Follow the instructions below in case of spillage:
protective clothing should be worn
broken glass should be collected and placed in the container for
contaminated surfaces should be flushed properly with copious amounts
of cold water
the flushed surfaces should then be wiped thoroughly and the materials
used for wiping should be disposed of as HAZARDOUS WASTE.
Preparation of the infusion solution
Irinotecan EGIS is intended for intravenous infusion only after diluting prior to
administration in the recommended diluents, either 0.9 % sodium chloride solution for
infusion or 5% glucose solution for infusion. Aseptically withdraw the required
amount of Irinotecan EGIS concentrate for solution from the vial with a calibrated
syringe and inject into a 250 ml infusion bag or bottle. The infusion should be
thoroughly mixed by manual rotation.
If any precipitate is observed in the vials or after dilution, the product should be
discarded according to standard procedures for cytotoxic agents.
This medicinal product must not be mixed with other medicinal products except those
Irinotecan EGIS solution for infusion should be infused into a peripheral or central
Irinotecan EGIS should not be delivered as an intravenous bolus or an intravenous
infusion shorter than 30 minutes or longer than 90 minutes.
After dilution: the solution should be used immediately as it contains no antibacterial
preservative. If reconstitution and dilution are performed under strict aseptic
conditions (e.g. on Laminar Air Flow bench) the solution should be used (infusion
completed) immediately or within24 hours if stored at 2°-8°C after the first opening.
All items used for preparation, administration or otherwise coming into contact with
Irinotecan EGIS should undergo disposal according to local guidelines for the
handling of cytotoxic compounds.
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.